A new graphical format to communicate treatment effects to patients—A web-based randomized controlled trial by Kasper, Jürgen et al.
Health Expectations. 2017;20:797–804.	 	 	 | 	797wileyonlinelibrary.com/journal/hex
Accepted: 29 October 2016
DOI: 10.1111/hex.12522
O R I G I N A L  R E S E A R C H  P A P E R
A new graphical format to communicate treatment effects to 
patients—A web- based randomized controlled trial
Jürgen Kasper Prof. Dr. phil1,2,3 | Adrian van de Roemer Dr. rer nat4 | Jana Pöttgen Dr. phil5 |  
Anne Rahn M.Sc3,5 | Imke Backhus M.Sc5 | Yasemin Bay Dr. med5 | Sascha Köpke Prof. Dr. 










































Objective: Patients	 making	 treatment	 decisions	 require	 understandable	 evidence-	
based	information.	However,	evidence	on	graphical	presentation	of	benefits	and	side-	
effects	of	medical	treatments	is	not	conclusive.	The	study	evaluated	a	new	space-	saving	
format,	 CLARIFIG	 (clarifying	 risk	 figures),	 aiming	 to	 facilitate	 accuracy	 of	
comprehension.
Methods: CLARIFIG	displays	groups	of	patients	with	and	without	treatment	benefits	
as	 coloured	 sectors	 of	 a	 proportional	 bar	 graph	 representing	 in	 total	 100	patients.	
Supplementary	icons	indicate	the	corresponding	group’s	actual	condition.	The	study	
used	an	application	showing	effects	of	immunotherapy	intended	to	slow	disease	pro-
gression	 in	multiple	 sclerosis	 (MS).	 In	a	 four-	arm	web-	based	 randomized	controlled	
trial,	 CLARIFIG	 was	 compared	 to	 the	 reference	 standard,	 multifigure	 pictographs	





CLARIFIGstatic=44%; P=.59;	 MFPanimated=23%,	 CLARIFIGanimated=30%; P=.134).	
Processing	 time	 for	 CLARIFIG	 was	 shorter	 only	 in	 the	 animated	 version	
(MFPstatic=162	seconds,	 CLARIFIGstatic=155 seconds; P=.653;	 MFPanimated=286 sec-
onds,	 CLARIFIGanimated=189 seconds; P≤.001).	 However,	 both	 animated	 versions	
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To	 be	 able	 to	 make	 informed	 choices	 about	 immunotherapies,	
MS	 patients	 need	 information	 prepared	 in	 line	with	 the	 criteria	 of	
evidence-	based	patient	information.4,5	These	criteria	require	commu-
nication	of	benefits	and	harm	for	each	option	presented	as	changes	of	
absolute	risk	together	with	an	estimation	of	 the	 information’s	 trust-
worthiness.	Furthermore,	 the	criteria	 include	presenting	event	 rates	
by	the	additional	use	of	graphical	frequency	formats.	Previous	stud-
ies	 have	 shown	 that	 different	 graphical	 formats	visualizing	 probabi-
listic	 information	using	 bar	 graphs,	 survival	 curves	 and	 pie	 charts4,6 
improve	 patients’	 understanding7	 and	 even	 the	 quality	 of	 physician	 
patient	communication8,9	when	compared	 to	 text-	only	 risk	 informa-
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2  | METHODS
2.1 | Design




with	 a	 corresponding	 application	 of	 the	 MFP	 reference	 standard	
(Figure	1)	and	with	animated	versions	of	the	two	graphs,	respectively.











(iii)	 patients	who	do	not	benefit	because	 the	 intended	 result	would	
have	 occurred	 naturally.	 Applied	 to	 the	 study	 information	 exam-
ple,	 CLARIFIG	 shows	 dichotomous	 outcome	 (benefit	 vs	 no	 benefit)	
indicated	by	the	colour	of	the	bar	graph	segment	and	three	different	
types	of	results	as	described	above:	(i)	patients	remaining	stable	as	a	


















ing	 the	primary	end	point.	The	 calculation	was	based	on	 two-	sided	
testing	with	a	5%	alpha	error	and	a	90%	power.	Compensating	a	20%	




Visitors entering the study course (n = 889)
Excluded (n=207)
Not meeting inclusion criteria (n = 41) 
Did not continue until randomisation (n = 166) 
Lost to follow-up (n = 4) 
Allocated to 
MFP static 
(n = 193) 
Allocated to
CLARIFIG animated 
(n = 158) 
Analysis
Follow-Up




(n = 171) 
Allocated to
CLARIFIG static 
(n = 160) 
Allocation
Lost to follow-up (n = 11) Lost to follow-up (n = 7) Lost to follow-up (n = 2)
Analyzed                   
 prim. endpoint     
comprehension (n = 171) 
 sec. endpoint (n = 39)
Analyzed                 
 prim. endpoint 
comprehension (n = 160) 
sec. endpoint (n = 68)  
Analyzed                   
prim endpoint 
comprehension (n = 158)  
sec. endpoint (n = 48)
Analyzed                 
prim. endpoint 
comprehension (n = 193) 
sec. endpoint (n = 88)





invitation	teaser,	 study	 instructions,	 the	actual	 intervention	consist-





about	 the	 study	 aim	 emphasized	 usability	 and	 comprehensibility	 of	
the	presentation	 formats	 rather	 than	 the	participants’	performance.	
Although	aware	of	the	existence	of	various	study	arms,	participants	
were	 blinded	 towards	 their	 own	 allocation.	 Randomization	 was	









terferon	 treatment	 to	delay	disease	progression	varied	 slightly	with	
regard	to	length	(one	to	three	charts)	and	presentation	mode	(static	
vs	 animated).	 The	primary	end	point,	 comprehension,	was	 assessed	




Please answer the following questions referring to the graphic:
1 How many of 100 patients benefit from the treatment? 
2 How many of 100 patients do not have a benefit?
3 How many of 100 patients remain stable without Interferon?
4
Identify the correct explanation for the following fact:
Although stable during interferon treatment, patients might not benefit, because …
… it is uncertain, whether those patients’ extent of disability will 
increase in the future.
… those patients are not cured though.
… their condition did not improve.
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the	 questionnaire,	 the	 system	 registered	 a	 participant	 as	 a	 finisher.	
However,	 before	 the	 procedure	 was	 officially	 finished,	 participants	
were	additionally	asked	to	fill	in	a	numeracy	questionnaire.
2.5 | Measurements
The	 primary	 end	 point	was	 previously	 developed	 and	 tested	 as	 a	
measure	 of	 accurate	 comprehension	 of	 the	 given	 quantitative	 in-
formation.17	The	score	was	dichotomized,	defining	four	correct	an-











study	 presentation	 and	 until	 completion	of	 the	 primary	 end	 point	
questionnaire.	Systematic	variation	of	the	time	needed	to	complete	
the	 task	was	 caused	only	 by	 the	presentation	 format,	 as	 all	 other	
parts	 of	 the	 study	 were	 identical.	 Differences	 in	 processing	 time	
were	considered	important,	although	the	type	of	hardware	used	as	




nitive	 impairment,	 four	 ordinally	 scaled	 items	 of	 the	 HAQUAMS	
instrument	were	applied.21	 In	addition,	 the	questionnaire	assessed	
age,	education,	disease	course,	disease	duration,	medication	status	
and	 previous	 participation	 in	 related	 studies.	 Numeracy	 was	 as-




four	 study	 groups	 (Table	1)	 with	 regard	 to	 demography,	 disease-	
related	 data	 and	 numeracy.	 In	 the	 data	 matrix	 used	 by	 the	 stat-
isticians	 analysing	 the	 trial,	 the	 nature	 of	 the	 four	 conditions	 was	
disguised.	Participants	were	included	in	the	analyses	of	the	primary	
end	 point	 if	 they	 at	 least	 reached	 the	 place	 where	 the	 four-	item	
comprehension	test	was	provided.	Missing	values	were	counted	as	
“not	 correct.”	 Analyses	 of	 primary	 and	 secondary	 end	 points	were	























MFP static MFP animated CLARIFIG static CLARIFIG animated Total
n 193 171 160 158 682
Age 39.6	(10.7) 38.0	(10.9) 41.4	(10.9) 41.4	(11.0) 40.1	(10.9)
Disease	course
Early 13	(7%) 15	(9%) 6	(4%) 7	(4%) 41	(6%)
Relapsing	remitting 131	(68%) 101	(59%) 103	(64%) 99	(63%) 434	(63.6%)
Secondary	chronic 20	(10%) 28	(16%) 25	(16%) 24	(15%) 97	(14.2%)
Primary	chronic 14	(7%) 6	(4%) 10	(6%) 9	(6%) 39	(5.7%)
Unclear 15	(8%) 21	(12%) 16	(10%) 19	(12%) 71	(10.4%)
Female 143	(74%) 116	(67.8%) 113	(70.6%) 113	(71.5) 485	(71%)
University-	level	education 61	(31.6) 56	(32.7%) 47	(29.4%) 47	(29.4%) 47	(29.7%)
Wheelchair-	dependent 9	(4.7%) 14	(8.2%) 15	(9.4%) 10	(6.3%) 48	(7%)
Cognitive	impairment 2.5	(0.9) 2.3	(1.0) 2.3	(1.0) 2.5	(1.0) 2.4	(1.0)
Numeracy 2.14	(1.06) 2.22	(.95) 1.91	(1.1) 1.87	(1.1) 2.04	(1.1)
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completed	 the	study	 (for	demographic	data	see	Table	1)	by	at	 least	
finishing	the	primary	end	point	task.	The	rate	of	dropout	was	gener-
ally	low	(n=24,	2.7%),	but	differed	slightly	between	study	conditions	




The	 two	 formats	 did	 not	 differ	 with	 regard	 to	 frequencies	 of	
comprehension,	 neither	 in	 the	 static	 nor	 in	 the	 animated	 pres-
entation	 (MFPstatic=46%,	 CLARIFIGstatic=44%; P=.59;	 animated	
MFPanimated=23%,	 CLARIFIGanimated=30%; P=.134)	 (Table	2).	 Single	
correct	 answers	within	 the	 four-	item	 comprehension	 questionnaire	
were	more	 frequent;	 85%	of	 the	 participants	 identified	 the	 correct	
number	of	patients	benefiting	from	treatment	(Table	2).
For	 the	 static	 presentation,	 the	 animated	 formats	 led	 to	 signifi-
cantly	less	comprehension	and	longer	processing	time	(MFP:	P≤.001).
3.2 | Secondary end point
CLARIFIG	 showed	 advantages	 regarding	 processing	 time	 only	
in	 the	 animated	 version	 (MFPstatic=162	seconds.	 (SD	 100),	
CLARIFIGstatic=156	seconds.	 (SD	 76);	 P=.653;	 MFPanimated=286 sec-
onds	 (SD	 172),	 CLARIFIGanimated=188	seconds.	 (SD	 62);	 P≤.001).	
However,	compared	to	the	static	presentation,	the	animated	formats	
led	 to	 significantly	 less	 comprehension	 and	 longer	 processing	 time	
(MFP:	p	<=	.001	/	.001,	CALRIFIG:	p	=	.027/.017)	(Table	3).
Comprehension	 was	 unrelated	 to	 processing	 time	 in	 all	 study	













elements	 are	 a	 balanced	presentation	of	 possible	 benefits	 between	
various	medical	options	and	presentation	of	potential	harm	alongside	
presentation	of	benefits.	The	complex	nature	of	medical	decisions	jus-







correctly	 identified	 the	 proportion	 benefiting	 (9%),	 while	 <50%	 of	
participants	 in	all	conditions	fully	understood	this	figure	was	clearly	
below	50%	in	all	conditions.	We	are	not	aware	of	other	studies	using	
the	 latter	 instead	of	 the	 former	 parameter	 to	 assess	 understanding	
of	numerical	 risk	 information.	However,	our	choice	of	the	more	rig-








their	 physician,	 for	 example	 communicating	 relative	 risk	 reductions	
only.	The	knowledge	 that	positive	medical	 results	 (such	as	 absence	










Results in the four- item comprehension test
Format MFP CLARIFIG
Presentation Static Animated Static Animated
Sample	size 193 171 160 158
Question	1 86% 80% 86% 89%
Question	2 64% 71% 67% 43%
Question	3 86% 39% 91% 90%
Question	4 77% 75% 76% 82%
































resistance	 to	 accepting	 the	 information	 because	 of	 the	 low	 rate	 of	




















clear	presentation	of	comprehensive	 information.	With	 regard	 to	 its	
concise	format,	we	expect	CLARIFIG	to	 improve	comprehension	ac-








The	 stepwise	 (“animated”)	 appearance	 of	 the	 graphic	 elements	
used	 in	two	of	the	study	conditions	obviously	confused	participants	
rather	 than	 providing	 meaningful	 structure.	 Participants	 in	 the	 ani-
mated	conditions	performed	much	less	well	on	both	comprehension	
and	processing	 speed	 than	 those	 seeing	a	 stable	diagram.	Although	
contradicting	our	hypotheses,	this	finding	is	in	line	with	studies	from	








only	 patients	with	 a	 special	 interest	 or	 competence	might	 have	 ac-
cessed	the	study.	Most	of	the	patients	 in	our	sample	probably	were	
not	 currently	 involved	 in	 making	 decisions	 about	 immunotherapy,	
which	might	have	 limited	the	motivation	to	process	the	 information	















for	developers	and	users	of	 frequency	 formats.6	 In	 this	 respect,	our	















it	 compared	 the	methods	 in	 a	 limited	 application	using	 information	
from	just	one	isolated	study.	Having	found	low	comprehension	rates	
irrespective	 of	 the	 experimental	 condition,	 the	 study	 demonstrates	
the	 gap	 between	 recognizing	 and	 fully	 understanding	 the	 informa-
tion	on	 the	 rate	of	benefit.	This	 result	 implies	 that	 further	 research	
is	 needed	on	 strategies	 to	 establish	 realistic	 expectations	 regarding	






Fulcher.	 Gary	 died	 in	 July	 2015,	 and	 we	 are	 missing	 him	 greatly.	
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